Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.50 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.50 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | RGS12 | O14924 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10916439 | 0.82 | ALDH1A1 (1.00) | ALDH1A1KMT2AMEN1NPC1KDM4E | |
| SCHEMBL1545282 | 0.82 | ALDH1A1 (0.56) | ALDH1A1KMT2AMEN1NPC1KDM4E | |
| SCHEMBL4172596 | 0.82 | ALDH1A1 (0.70) | ALDH1A1KMT2AMEN1NPC1KDM4E | |
| SCHEMBL974759 | 0.81 | ALDH1A1 (0.69) | ALDH1A1KMT2AMEN1NPC1KDM4E | |
| SCHEMBL1544895 | 0.80 | ALDH1A1 (0.67) | ALDH1A1KMT2AMEN1KDM4EHPGD | |
| SCHEMBL10915111 | 0.79 | ALDH1A1 (0.66) | ALDH1A1KMT2AMEN1NPC1KDM4E | |
| SCHEMBL19520395 | 0.78 | SMN1; SMN2 (0.62) | ALDH1A1KMT2AMEN1NPC1KDM4E | |
| SCHEMBL14076996 | 0.77 | ALDH1A1 (0.47) | ALDH1A1KMT2AMEN1NPC1KDM4E | |
| SCHEMBL392037 | 0.74 | ALDH1A1 (0.44) | ALDH1A1KMT2AMEN1NPC1KDM4E | |
| SCHEMBL2004713 | 0.74 | ALDH1A1 (0.59) | ALDH1A1KMT2ANPC1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2311830-A1 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | AstraZeneca AB (SE) | 2011-04-20 | — | — | EP | disclosed |
| EP-2311830-A1 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | AstraZeneca AB (SE) | 2011-04-20 | — | — | EP | disclosed |
| EP-1723144-B1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2010-10-06 | — | — | EP | disclosed |
| EP-1723144-B1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2010-10-06 | — | — | EP | disclosed |
| US-7585881-B2 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2009-09-08 | — | — | US | disclosed |
| US-7585881-B2 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2009-09-08 | — | — | US | disclosed |
| US-7585881-B2 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2009-09-08 | — | — | US | disclosed |
| US-20080045571-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045571-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045571-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | disclosed |
| US-20050272779-A1 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB | 2005-12-08 | — | — | US | disclosed |
| EP-0495226-B1 | 3-Aryl-5-alkylthio-4H-1,2,4-triazoles for treatment of hyperreflexia due to spinal trauma | MERRELL DOW PHARMA (US) | 1995-10-11 | — | — | EP | disclosed |
| US-5260450-A | Anticonvulsants | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-11-09 | — | — | US | disclosed |
| EP-0276793-B1 | 3-ARYL-5-ALKYLTHIO-4H-1,2,4-TRIAZOLES | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-06-16 | — | — | EP | disclosed |
| US-5158968-A | 3-aryl-5-alkylthio-4H-1,2,4-traizoles for treatment of hyperreflexia due to spinal trauma | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-10-27 | — | — | US | disclosed |
| US-5143933-A | Anticonvulsants | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-09-01 | — | — | US | disclosed |
| EP-0495226-A2 | 3-Aryl-5-alkylthio-4H-1,2,4-triazoles for treatment of hyperreflexia due to spinal trauma | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-07-22 | — | — | EP | disclosed |
| US-4981863-A | ANTIANXIETY | MERRELL DOW PHARMACEUTICALS (US) | 1991-01-01 | — | — | US | disclosed |
| US-4900743-A | TREATING MUSCLE SPASMS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-02-13 | — | — | US | disclosed |
| EP-0276793-A2 | 3-Aryl-5-alkylthio-4H-1,2,4-triazoles | MERRELL DOW PHARMACEUTICALS INC. (US) | 1988-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272779-A1 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM5, GRIK5, GRM2 | ALDH1A1 3875/4885KMT2A 2030/4885MEN1 3387/4885 |
| US-20080045571-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | GRM5, GRIK5, GRM2 | ALDH1A1 3875/4885KMT2A 2030/4885MEN1 3387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.